Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 3370

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 3370
---
 we have outlined above.

Our
Therapeutic Programs

Oncology
Product Candidates for NSCLC and GBM

Our
oncology product candidates for NSCLC and GBM:

    ●
    OCX-253
    anti-Chi3l1 Single-target mAb (NSCLC)

    ●
    OCX-410
    anti-Chi3l1/PD-1 Bi-specific antibody (NSCLC)

    ●
    OCX-909
    anti-Chi3l1/CTLA-4 Bi-specific antibody (GBM)

Our
product candidates in our oncology program are based on a drug target pioneered by Dr. Elias. His research demonstrated that a protein
called chitinase 3-like-1, or Chi3l1, is a key driver of multiple disease pathways in primary and metastatic tumor development demonstrating
an 85-95% reduction in primary and metastatic tumor burden in multiple animal models. Animal models of lung cancer and glioblastoma,
a type of brain cancer, showed that inhibition of Chi3l1 resulted in statistically significant tumor reduction – even more so when
combined with immunotherapies to stimulate the body’s own immune response against cancer. Our oncology development pipeline consists
of: (a) an antibody therapeutic product candidate inhibiting Chi3l1; (b) a bi-specific antibody product candidate inhibiting Chi3l1 plus
PD-1, a checkpoint inhibitor protein; and (c) a bi-specific antibody product candidate inhibiting Chi3l1 plus CTLA-4, another checkpoint
inhibitor protein. These product candidates are targeting non-small cell lung cancer, or NSCLC, which accounts for about 85% of all lung
cancers globally and affects about 460,000 people in the United States and 595,000 people in Europe, and glioblastoma multiforme, or
GBM, a brain cancer that kills approximately 60% of patients within 12 to 18 months from the time of diagnosis and for which new treatment
therapies are needed.

Non-Small
Cell Lung Cancer

Lung
cancer is the most common cancer worldwide, accounting for 2.1 million new cases and 1.8 million deaths in 2018. In the United States,
lung cancer is the third most common and the deadliest malignancy. Approximately 541,000 people in the United States today have been
diagnosed